# US 2019/0243946 A1 · Optimizing Successful Outcomes for Repurposing Existing Pharmaceutical Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0243946 A1
- Document ID: US20190243946A1
- Status: Published application
- Kind: A1
- Application number: 16/038,346
- Filed: 2018-07-18
- Published: 2019-08-08
- Earliest claimed: 2018-02-02
- Inventors: Richard Postrel
- Web page: https://patentgrep.com/patent/US20190243946A1

## CPC

- G16C 20/40: Searching chemical structures or physicochemical data
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- C40B 30/00: Methods of screening libraries
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G06F 16/2455: Query execution
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 40/20: Supervised data analysis
- G16C 20/50: Molecular design, e.g. of drugs
- G16C 20/70: Machine learning, data mining or chemometrics
- G16C 20/90: Programming languages; Computing architectures; Database systems; Data warehousing
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 70/40: relating to drugs, e.g. their side effects or intended usage
- A61K 31/52: Purines, e.g. adenine
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention provides a process and method for preventing and/or treating protein based diseases, including, but not limited to: Alzheimer's and other amyloid based disease groups. This method recognizes correlative similarities across genomics, phenotypic and pharmacologic analytics and data to identify a list of existing compounds as high probability targets to act as inhibitors and/or stimulants close to a disease of interest. Pertinent genetic or epigenetic variances, or protein expression anomalies, are used to assemble a list of existing compounds through the use of artificial intelligence, machine learning and algorithmic relationships. This invention applies current genomic, phenotypic and pharmacological data to leverage data previously obtained in pursuit of other disease treatments. Accordingly, the current invention collapses cycle time to discovery and dramatically reduces costs. Through this system of active compounds created from tenuous relationships exhibits an elevated probability of success. Using a selection of algorithms that coordinate relationships including, but not limited to: genomic, epigenomic, phenotypic, protein dysregulation, cultural, pharmacological, etc., data, the present invention collapses cycle time of development and dramatically reduces costs by accessing data on target rich groups of previously tested abstractly related compounds.

## Claims

### Claim 1

An improved method for repurposing a known compound for use in treating a disease for which said compound was not clinically prescribed comprising:
a. Initiating process by identifying a genomic variance;
b. Inputting said variance into a database system;
c. Outputting a list of medical correlates, showing a relation to said variance;
d. Inputting said list into a database system;
e. Applying an artificially intelligent algorithm in outputting a second list of correlates comprising at least one feature selected from the group consisting of: genomic variances, cultural associations, location of medical events, chemical modulations, homeopathic modulations, cultural knowledge, timing of correlation event and treatment outcome;
f. Optionally reapplying said artificially intelligent algorithm to expand or focus said second list;
g. Optionally applying a second artificially algorithm to said output product of e to expand or focus said second list;
h. Repeating f and/or g as desired—including 0 times, if desired, and outputting said result(s);
i. Obtaining one or more biomodels comprising a genomic variance or product of a genomic variance identified in a and/or h;
j. Applying a compound or composition identified in h to at least one said biomodel;
k. Associating said genomic variance of said biomodel of j with a disease or symptom and scheduling further testing of said compound or composition with said disease or symptom; and
l. Supporting marketing for pharmaceutical or supplemental use of at least one said compound or composition whose testing exhibited positive result.

### Claim 2 (depends on 1)

The improved method of claim 1 wherein said location is selected from the group consisting of: a geographic location, an altitude a vehicle, an organ, a tissue, a part of the anatomy and a biopsied sample.

### Claim 3 (depends on 1)

The improved method of claim 1 wherein said one or more biomodels comprises at least one transgenic mouse.

### Claim 4 (depends on 1)

The improved method of claim 1 wherein said supporting comprises filing a patent application.

### Claim 5

A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:
a. selecting i) a symptom or disease or ii) genomic variance;
b. feeding i) or ii) into a search field of a structured database;
c. querying said at least one structured database for content of one or a plurality of records referencing i) or ii);
d1. for i) selecting at least one record referencing a first genomic variance:
d2. for ii) selecting at least one record referencing a first symptom or disease;
e. correlating results of dx (where x=1 or 2) with at least one recorded feature of said at least one record;
f. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
g. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
h. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:
i. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;
j. determining effect of said one or more compounds and/or compositions;
k. selecting one or more compounds and/or compositions determined to have desired effect; and
l. identifying at least one of one or more compounds and/or compositions selected in k as said new pharmaceutical composition; or:
j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;
k. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
l. selecting at least a second compound or composition to counteract at least one of said one or more undesired outcome(s);
m. confirming desired activity of said at least one second compound or composition; and
n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

### Claim 6

A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:
d. selecting i) a symptom or disease or ii) genomic variance;
e. feeding i) or ii) into a search field of a structured database;
f. querying said at least one structured database for content of one or a plurality of records referencing i) or ii);
d1. for i) selecting at least one record referencing a genomic variance:
d2. for ii) selecting at least one record referencing a symptom or disease;
m. correlating results of dx (where x=1 or 2) with at least one recorded feature of said at least one record;
n. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
o. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
p. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:
q. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;
r. determining effect of said one or more compounds and/or compositions;
s. selecting one or more compounds and/or compositions determined to have desired effect; and
t. identifying at least one of one or more compounds and/or compositions selected in k as said new pharmaceutical composition; or:
o. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;
p. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
q. selecting at least a second compound or composition to counteract at least one of said one or more undesired outcome(s);
r. confirming desired activity of said at least one second compound or composition; and
s. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

### Claim 7

A method for identifying a new pharmaceutical composition for treating a disease, said method comprising:
a. selecting a first symptom or a first genomic variance;
b. optionally: querying a database for a correlative relationship between said first symptom and a correlate genomic variance or between said first genomic variance and a correlate symptom;
c. querying at least one database with at least one selection of a and/or at least one correlate of b to provide an identification of a first disease;
d. accessing at least one structured database;
e. querying said at least one structured database for content of one or a plurality of records referencing said first disease;
f. selecting at least one record referencing said first disease;
g. correlating said first disease with at least one recorded feature of said at least one record;
h. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
i. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
j. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one disease; and:
k. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in i and remaining after j;
l. determining effect of said one or more compounds and/or compositions;
m. selecting one or more compounds and/or compositions determined to have desired effect; and
n. identifying at least one of one or more compounds and/or compositions selected in I as said new pharmaceutical composition; or:
k. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in j;
l. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
m. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of said one or more undesired outcome(s);
n. confirming desired activity of said at least one second compound or composition; and
o. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

### Claim 8 (depends on 5)

The method of claim 5 further comprising:
m. or o. delivering said new pharmaceutical composition to at least one individual.

### Claim 9 (depends on 6)

The method of claim 6 further comprising:
o. or p. delivering said new pharmaceutical composition to at least one individual.

### Claim 10 (depends on 8)

The method of claim 8 wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 11 (depends on 9)

The method of claim 9 wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 12 (depends on 5)

The method of claim 5 wherein at least one of said at least one undesired outcome(s) is selected from the group consisting of: countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, 02 consumption and interferon production

### Claim 13 (depends on 6)

The method of claim 6 wherein at least one of said at least one undesired outcome(s) is selected from the group consisting of: countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, 02 consumption and interferon production

### Claim 14

A method for producing a new pharmaceutical composition, said method comprising:
a. selecting a first symptom of a first disease;
b. providing an identification of said first disease;
c. accessing at least one structured database;
d. querying said at least one structured database for content of one or a plurality of records selected from the group consisting of: record(s) referencing said first symptom and record(s) referencing said first disease;
e. selecting at least one first record obtained from d;
f. selecting at least one chemical compound relating to said at least one first record;
g. querying at least one structured database for content of one or a plurality of records referencing said at least one chemical compound to obtain a listing comprising diseases and symptoms relating to said compound;
h. querying at least one structured database with results of said listing obtained from the query in g to obtain a compilation of compounds associated with symptoms or diseases of said listing;
i. analyzing compounds related in f. and h. for similarities and distinctions;
j. querying at least one structured database for negative assessments of compounds related in f. and h.;
k. correlating negative assessments with similarities and distinctions of i.;
l. associating chemical structure with said similarities and distinctions;
m. selecting chemical structural features minimizing said negative assessments;
n. designing a chimeric compound or a library of chimeric compounds maintaining at least one feature of at least one compound related in f. and h. while discarding one or more chemical feature selected in m.; and
o. producing at least one compound designed in n.

### Claim 15 (depends on 14)

The method of claim 14 further comprising:
e1. querying at least one structured database for a compound previously applied to modulate at least one characteristic associated with said first symptom or said first disease to obtain a compound identifying record; and
in f. selecting a chemical compound relating to said compound identifying record.

### Claim 16 (depends on 5)

The method of claim 5 further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said new pharmaceutical composition.

### Claim 17 (depends on 6)

The method of claim 6 further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said compound designed in n.

### Claim 18 (depends on 5)

The method of claim 5 further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said new pharmaceutical compound or composition.

### Claim 19 (depends on 5)

A pharmaceutical composition identified in accordance with claim 5.

### Claim 20 (depends on 19)

The composition of claim 19 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 21 (depends on 6)

A pharmaceutical composition identified in accordance with claim 6.

### Claim 22 (depends on 21)

The composition of claim 21 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 23 (depends on 18)

A pharmaceutical composition comprising a compound produced in accordance with claim 18.

### Claim 24 (depends on 23)

The composition of claim 23 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 25 (depends on 22)

The pharmaceutical composition of claim 22 in a delivery format selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 26 (depends on 23)

The composition of claim 23 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); Δ9-tetrahydrocannabivarinic (THCV); Δ7-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LΔ−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 27 (depends on 25)

The composition of claim 25 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 28 (depends on 21)

The composition of claim 21 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); Δ9-tetrahydrocannabivarinic (THCV); Δ7-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 29 (depends on 28)

The composition of claim 28 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 30 (depends on 23)

The composition of claim 23 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); A9-tetrahydrocannabivarinic (THCV); A′-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 31 (depends on 30)

The composition of claim 30 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 32 (depends on 5)

The method of claim 5 wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said symptom is not identical to said second symptom or said disease is not identical to said second disease.

### Claim 33 (depends on 6)

The method of claim 6 wherein said new pharmaceutical composition is applied to treating a second disease wherein said first disease is not identical to said second disease.

### Claim 34 (depends on 18)

The method of claim 18 wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said first symptom is not identical to said second symptom or said first disease is not identical to said second disease.
